Compare Natera Inc. Common Stock (NTRA) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Clear Secure Inc — how do they compare? Natera Inc. Common Stock trades at $394.16 (market cap $57.03B), while Clear Secure Inc trades at $44.26 (market cap $4.49B). The key difference: Natera Inc. Common Stock is far larger — about 12.7× Clear Secure Inc's market cap, and Clear Secure Inc pays a 1.32% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Clear Secure Inc for 20 Days on average.
| NTRA | YOU | |
|---|---|---|
Market Cap | $57.03B | $4.49B |
Volume | 1,131,157 | 1,674,277 |
Sector | Health | Technology |
52-Week High | $425.64 | $62.36 |
52-Week Low | $179.42 | $30.47 |
Typical Hold Time | 0 Days | 20 Days |
Enterprise Value | $56.18B | $3.64B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Clear Secure (YOU) trades at $43.52, up 2.5% over the past day, with a mixed technical picture showing bearish moving averages but neutral oscillators. Fundamentally, the company reported strong Q2 2026 results with EPS of $0.49 beating estimates, revenue growth of 27% year-over-year, and robust profitability metrics including a 66.66% gross margin. Recent developments include a strategic partnership with CrowdStrike and the launch of corporate memberships.
The outlook is positive given accelerating membership growth and expanding margins, though risks include competitive pressures and reliance on airport services. Analysts are generally bullish with a consensus price target of $61.40, representing significant upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
